Halliburton, Baker Hughes Deal Resurrected

The transcript discusses the revival of the Halliburton-Baker Hughes deal, highlighting the role of financial incentives and market conditions. It explores the impact of low oil prices on smaller companies and the regulatory challenges faced by the merger. Additionally, it covers the involvement of activist investors in the Actavis-Valiant deal, emphasizing the financial complexities and market dynamics involved.

What was the main reason for the revival of the Halliburton and Baker Hughes deal?

• A change in leadership

• A new competitor entering the market

• A decrease in oil prices

• An increase in the offer

What is a major regulatory concern for the Halliburton and Baker Hughes merger?

• Inadequate revenue generation

• Lack of market overlap

• Insufficient termination fee

• Excessive market overlap

How much revenue is Halliburton willing to sell to address regulatory concerns?

• Ten billion dollars

• Seven and a half billion dollars

• Five billion dollars

• Three billion dollars

What is the market cap of Actavis as mentioned in the discussion?

• $55 billion

• $60 billion

• $65 billion

• $70 billion

Why is the Actavis and Valiant deal considered unlikely to proceed?

• Market competition

• Regulatory disapproval

• Excessive debt for Valiant

• Valiant's lack of interest